| abstract |
Use of (i) a tricyclic antidepressant; and (ii) a prednisolone for the preparation of a medicament for treating a patient who has an inflammatory disorder or a patient at risk of developing an inflammatory disorder, wherein said tricyclic antidepressant is selected from amoxapine, 8-hydroxyamoxapine, 7-hydroxyamoxapine, loxapine, loxapine succinate, loxapine hydrochloride, 8-hydroxyloxapine, amitriptyline, clomipramine, imipramine, trimipramine, desipramine, nortriptyline, and protriptyline, and where drugs (i) and (ii) are administered by oral, rectal, intravenous administration, intramuscularly, subcutaneously, by inhalation, vaginal, or ophthalmic simultaneously or within 14 days of separation, in amounts sufficient to reduce or inhibit inflammation in said patient. |